Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

QNZ

Catalog No: tcsc1515

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
545380-34-5

Formula:
$C_{22}H_{20}N_4O$

Pathway:
Apoptosis;NF-κB

Target:
TNF Receptor;NF-κB

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 37 mg/mL (103.81 mM)

Alternative Names:
EVP4593

Observed Molecular Weight:
356.42

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

QNZ shows strong inhibitory effects on **NF-κB** transcriptional activation and **TNF-α** production with **IC_{50}**s of 11 and 7 nM, respectively. EVP4593 is a neuroprotective inhibitor of **SOC** channel.

IC50 & Target: IC50: 7 nM (TNF-α), 11 nM (NF-κB)[1]

SOC Channel[2]

In Vitro: QNZ (Compound 11q) has a suppressing effect of the NF-κB mediated-inflammatory response. QNZ inhibits edema formation dose-dependently[1]. QNZ (EVP4593) reduces the number of lysosomes/autophagosomes and store-operated channel (SOC) currents in Huntington\'s disease (HD). Normalization of calcium transport within neurons in response to QNZ is expect to reduce pathology manifestation. A number of lysosomes/autophagosomes are evaluated in HD and WT neurons treated with QNZ using transmission electron microscopy (TEM). Incubation with QNZ reduces the number of lysosomes/autophagosomes in HD GABAergic medium spiny (GABA MS)-like neurons (GMSLNs) by almost two-fold (from 0.41±0.04 to 0.23±0.04; p[2].